AK3280

DRUG4 trials

Sponsors

Shanghai Ark Biopharmaceutical Co., Ltd.

Conditions

HealthyIdiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)

Phase 1

A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects

CompletedNCT03990688

Shanghai Ark Biopharmaceutical Co., Ltd.Healthy

Start: 2019-10-03End: 2020-09-21Updated: 2021-06-09

A Study of AK3280 in Chinese Healthy Volunteers

CompletedNCT04926116

Shanghai Ark Biopharmaceutical Co., Ltd.Healthy

Start: 2021-06-09End: 2021-09-28Updated: 2022-04-07

Phase 2

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Shanghai Ark Biopharmaceutical Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2022-07-31End: 2024-10-31Target: 105Updated: 2022-07-20

Phase 3

A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Not yet recruitingNCT07719023

Shanghai Ark Biopharmaceutical Co., Ltd.Idiopathic Pulmonary Fibrosis (IPF)

Start: 2026-08-31End: 2029-03-31Target: 263Updated: 2026-07-22